Genentech’s first campaign for eye drug Vabysmo is literally eye-opening. In the debut TV commercial, a woman opens an eye-shaped
Use of Trudhesa as an acute migraine treatment is on par with the more-established Reyvow, though future projections have it
Although providers are optimistic about the potential of a new treatment for Alzheimer’s, some are concerned that the burden of monitoring the
U.S. neurologists are “cautiously optimistic” about using Eisai’s Leqembi in Alzheimer’s disease as concerns about safety and the need for
Use of Qulipta as a preventive migraine treatment still trails Nurtec ODT, but future projections have the brands’ use on
Release of second annual EU5 research on IgA nephropathy highlights unmet needs, regional diagnosis and treatment trends, and awareness of
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As
Growth of newer market entrants resulting in relatively flat projected share for Eli Lilly’s Emgality, Teva’s Ajovy, and Amgen’s Aimovig
Ten NAFLD/NASH pipeline product profiles were evaluated by US gastroenterologists and hepatologists to assess strengths, weaknesses, and physician receptivity EXTON,
In 2021, the number of private equity acquisitions of gastroenterology practices grew by 28% over the previous year, according to
Roche trumpeted a “major advancement” in the retinal space with the approval of its eye drug Susvimo last October, touting
Almost half, 49 percent, of rheumatologists, decreased prescriptions of Xeljanz over the past three months, according to Spherix Global Insights’
